it is without doubt the most effective treatment for hairy-cell leukemia, in terms of rapidity of response, adds elihu h. estey, a cancer researcher at the university of texas-m.d. anderson cancer center, houston. hairy-cell leukemia, so-called because of the appearance of the cancerous cells under the microscope, affects about 6,000 people in the u.s., with 600 new cases a year. since then, alpha interferon, a drug sold by hoffmann-la roche inc. and schering-plough corp. and an experimental drug called deoxycoformycin have significantly reduced death rates from hairy-cell leukemia. with the lack of toxicity and the ease with which people go into remission {with 2-cda}, i think there's something really going on here, says ellin berman, a staff leukemia doctor at memorial sloan kettering cancer center, new york. because hairy-cell leukemia is rare, a 12-patient study is considered a pretty good series, says sloan-kettering's dr. berman. because hairy-cell leukemia is rare, a 12-patient study is considered a pretty good series, says sloan-kettering's dr. berman. dr. piro said 2-cda has also been used effectively in initial trials to treat more common cancers, including chronic lymphocytic leukemia, non-hodgkins lymphoma and cutaneous t-cell lymphoma. 